156
Views
1
CrossRef citations to date
0
Altmetric
Short report

Online availability of gabapentin and pregabalin and the impact of legal reclassification in the United Kingdom

ORCID Icon, &
Pages 222-226 | Received 20 Nov 2019, Accepted 08 Jul 2020, Published online: 08 Feb 2022
 

Abstract

Background

Concerns about the misuse of gabapentin and pregabalin and an increase in related deaths led to these drugs being classified as controlled substances in the United Kingdom (UK) in April 2019. This study investigates the online availability of gabapentin and pregabalin, from the perspective of a UK-based consumer, and whether the change in legislation was associated with any change in availability.

Methods

An internet snapshot survey for the availability and prescription requirements of gabapentin and pregabalin was undertaken, using established European methodology, two months before (February 2019) and two months after (June 2019) the legislation change.

Results

A total of 70 websites selling gabapentin and/or pregabalin to UK-based customers were identified in February 2019 compared to 56 websites in June 2019. No significant difference was observed for the proportion of websites requiring a prescription before and after legislation change for either gabapentin (p = 0.574) or pregabalin (p = 0.223). Despite legislation change, 22 (47.8%) gabapentin websites and five (33.3%) pregabalin websites specifically stated no prescription was required to purchase the drugs in June 2019.

Conclusions

The change in legislation was associated with a decrease in online availability with fewer websites offering drugs for sale. However, these drugs remain widely available to purchase via some online pharmacies without a prescription which has significant public health implications.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.